Contrast Media Industry Growth by 2026

The Rising prevalence of chronic diseases, rising volume of CT and MRI examinations performed, growing approvals of contrast agents, growing number of diagnostic centers and hospitals, and availability of reimbursement are the major factors driving the growth of the contrast agents market.

According to research report Contrast Media Market is projected to $5.9 billion by 2026, at a CAGR of 3.7%.

Based on type, the contrast media market is segmented into iodinated contrast media, microbubble contrast media, gadolinium-based contrast media, barum-based contrast media. Iodinated contrast media account for the largest share of the market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.

The contrast media market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America was the largest regional market in 2020. The large share of the North American market can be attributed to presence of major players in the region, growing geriatric population, high prevalence of chronic disorders and the increasing adoption of minimally invasive procedures.

The global contrast media market is consolidated. The prominent players operating in this market include GE Healthcare (US), Guerbet (France), Bracco Imaging SPA (Italy), Bayer AG (Germany), J.B. Chemicals and Pharmaceuticals Ltd. (India), Lantheus Medical Imaging, Inc. (US), Unijules Life Sciences Ltd. (India), and SANOCHEMIA Pharmazeutika GmbH (Austria).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911